NCT02021422View on ClinicalTrials.gov

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

PHASE1UnknownINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Pancreas Cancer
Interventions
DRUG

anakinra

Dosage Route Administration 100 mg SC Every Other Day

DRUG

Oxaliplatin

Oxaliplatin 85 mg/m2 2-4 hours

DRUG

Irinotecan

Irinotecan 180 mg/m2 90 minutes

DRUG

fluorouracil

fluorouracil 2400 mg/m2 48 hours

Trial Locations (1)

75246

Baylor Sammons Cancer Center, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER

NCT02021422 - A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy | Biotech Hunter | Biotech Hunter